-
1.发明公开ENZYMATICALLY-PRODUCED DIMERIC IL-2 AND A NERVE-DERIVED TRANSGLUTAMINASE ENZYME FOR ITS PREPARATION 失效酶法MADE二聚体IL-2和1名神经WON谷氨酰胺转胺酶所作的介绍的。
公开(公告)号：EP0610475A1
公开(公告)日：1994-08-17
申请号：EP93918528.0
申请日：1993-07-30
Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.
Inventor： SCHWARTZ, Michal , EITAN, Shoshana
CPC classification number: C12N9/1044 , A61K38/00 , C07K14/55
Abstract: L'invention se rapporte à une nouvelle enzyme, la transglutaminase, derivée du nerf optique et qui transforme l'IL-2 immune dérivée en IL-2 dimère ayant une activité cytotoxique sur les oligodendrocytes. La transglutaminase dérivée du nerf optique et l'IL-2 dimère de mammifères, tels que l'homme, sont toutes les deux utilisées comme ingrédients actifs dans des compositions pharmaceutiques afin d'introduire et de faciliter la régénération des nerfs lésés du système nerveux central des mammifères.
-
2.发明公开A METHOD FOR TREATING OR INHIBITING THE EFFECTS OF INJURIES OR DISEASES THAT RESULT IN NEURONAL DEGENERATION 审中-公开方法治疗或抑制伤害或疾病的影响神经元变性LEAD
公开(公告)号：EP1673097A2
公开(公告)日：2006-06-28
申请号：EP04788634.6
申请日：2004-09-08
Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.
Inventor： SCHWARTZ, Michal , LIDER, Ofer , ROLLS, Asya , CAHALON, Liora
IPC: A61K31/7016 , A61K31/702
CPC classification number: A61K31/7016 , A61K31/702 , A61K31/727 , A61K31/728 , A61K31/737
Abstract: Oligosaccharides, and in particular disaccharides, which are degradation products of chondroitin sulfate proteoglycan are effective for use in treating, inhibiting, or ameliorating the effects of injuries or diseases or disorders that result in or are caused by neuronal degeneration or of disorders resulting in mental and cognitive dysfunction.
-
3.发明授权NERVE-DERIVED TRANSGLUTAMINASE ENZYME USEFUL FOR INDUCING NERVE REGENERATION 失效患有神经性得到谷氨酰胺转胺酶神经再生的诱导
公开(公告)号：EP0610475B1
公开(公告)日：2002-03-20
申请号：EP93918528.6
申请日：1993-07-30
Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.
Inventor： SCHWARTZ, Michal , EITAN, Shoshana
CPC classification number: C12N9/1044 , A61K38/00 , C07K14/55
Abstract: The invention provides a new nerve-derived transglutaminase enzyme that converts immune-derived IL-2 to dimeric IL-2 having oligodendrocyte cytotoxic activity. Both the nerve-derived transglutaminase and the dimeric mammalian, e.g. human, IL-2, are for use as active ingredients in pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals.
-
-
Search Results
3
records
(took 0.027 seconds)
